ArticleThe Journal of experimental medicine2022
Ly49E separates liver ILC1s into embryo-derived and postnatal subsets with different functions.
Article in The Journal of experimental medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- ASB2 inhibits lipid accumulation to promote ILC1 homeostatic fitness and anti-tumor immunity in the mouse liver.Nature communications · 2026Article
- Multifaceted Role of ILCs in Metabolic Adaptations: From Adult to Neonate.European journal of immunology · 2025Review
- Role of liver-resident NK cells in liver immunity.Hepatology international · 2025Review
- GPR34 is a metabolic immune checkpoint for ILC1-mediated antitumor immunity.Nature immunology · 2024Article
- Immune surveillance of cytomegalovirus in tissues.Cellular & molecular immunology · 2024Review
- Article
- Group 1 ILCs: Heterogeneity, plasticity, and transcriptional regulation.Immunological reviews · 2024Review
- Cancer immunity by tissue-resident type 1 innate lymphoid cells and killer innate-like T cells.Immunological reviews · 2024Review
- Type 1 immunity enables neonatal thymic ILC1 production.Science advances · 2024Article
- Control of the Development, Distribution, and Function of Innate-Like Lymphocytes and Innate Lymphoid Cells by the Tissue Microenvironment.Advances in experimental medicine and biology · 2024Review
- Innate lymphoid cells-Underexplored guardians of immunity.PLoS pathogens · 2023Article
- Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells.Clinical and experimental medicine · 2023Review
- Genetic distinction between functional tissue-resident and conventional natural killer cells.iScience · 2023Article
- Article
- CD90 is not constitutively expressed in functional innate lymphoid cells.Frontiers in immunology · 2023Article
- Acute murine cytomegalovirus infection boosts cell-type specific response and lipid metabolism changes in the liver of infant mice.Frontiers in immunology · 2023Article
- Tissue-specific transcriptional profiles and heterogeneity of natural killer cells and group 1 innate lymphoid cells.Cell reports. Medicine · 2022Article
- The unique role of innate lymphoid cells in cancer and the hepatic microenvironment.Cellular & molecular immunology · 2022Review
- NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis.International journal of molecular sciences · 2022Review
- Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 innate lymphoid cells (ILC1s) represent the predominant population of liver ILCs and function as important effectors and regulators of immune responses, but the cellular heterogeneity of ILC1s is not fully understood. Here, single-cell RNA sequencing and flow cytometric analysis demonstrated that liver ILC1s could be dissected into Ly49E+ and Ly49E- populations with unique transcriptional and phenotypic features. Genetic fate-mapping analysis revealed that liver Ly49E+ ILC1s with strong cytotoxicity originated from embryonic non-bone marrow hematopoietic progenitor cells (HPCs), persisted locally during postnatal life, and mediated protective immunity against cytomegalovirus infection in newborn mice. However, Ly49E- ILC1s developed from BM and extramedullary HPCs after birth, gradually replaced Ly49E+ ILC1s in the livers with age, and contained the memory subset in recall response to hapten challenge. Thus, our study shows that Ly49E dissects liver ILC1s into two unique subpopulations, with distinct origins and a bias toward neonatal innate or adult immune memory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.